Perspective Therapeutics presents NET trial data
- Perspective Therapeutics (NYSE:CATX) will present updated data from its [212Pb]VMT-α-NET program at the 2026 EORTC-NCI-AACR Symposium.
- The presentation will include safety and efficacy results from Cohorts 1–3 in advanced SSTR2-positive neuroendocrine tumors.
- The company is evaluating the therapy in an ongoing Phase 1/2 clinical trial for unresectable or metastatic tumors.
Perspective Therapeutics (NYSE:CATX) announced that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona.
The poster will present cohort-level safety and efficacy results from Cohorts 1–3 of the clinical program evaluating [212Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors.
The presentation, led by Vikas Prasad of Washington University School of Medicine, will be included as Abstract 334 in the “New drugs” poster session on November 20, 2026.
The [212Pb]VMT-α-NET program is being evaluated in a multi-center, open-label, dose-escalation and dose-expansion trial involving patients with unresectable or metastatic SSTR2-positive tumors.
Perspective Therapeutics said additional data submissions from the program are planned for 2026 and 2027 as the clinical evaluation continues.
